Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2024-04-08 Regulatory Filings
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated April 8th, 2024, announcing that MaaT Pharma presented preclinical data at the AACR Annual Meeting. It details scientific findings, mentions ongoing clinical trials (Phase 3 for GvHD), and includes standard sections like 'About MaaT Pharma' and 'Forward-looking Statements', along with contact information for Investor Relations and Media. This format is characteristic of an announcement intended to inform investors and the public about recent developments, often related to research progress or upcoming events. Since it is not a full financial report (10-K, IR), a specific regulatory filing, or a transcript, the most appropriate classification is a general announcement. Given the context of presenting data and updates, it fits best under 'Regulatory Filings' (RNS) as a general corporate/research update, or potentially an 'Investor Presentation' (IP) if it were the presentation itself, but as a press release *about* the presentation, RNS is the best fit among the provided options, as it is a general regulatory/corporate communication.
2024-04-08 English
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated April 5th, 2024, announcing that the brokerage firm Gilbert Dupont/Groupe Société Générale initiated research coverage on MaaT Pharma's stock, including a 'Buy' recommendation and a Target Price. This type of announcement, which details external analyst initiation or updates, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, CAP, SHA). It is a general corporate update intended for investors regarding market perception and analyst coverage. Since it is a specific, non-standard announcement that doesn't fit the other defined categories, the most appropriate fallback is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous regulatory or market-related announcements not covered elsewhere.
2024-04-05 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release from MaaT Pharma, titled "MaaT Pharma annonce l'initiation de la couverture de son titre par Gilbert Dupont / Groupe Société Générale" (MaaT Pharma announces the initiation of coverage of its stock by Gilbert Dupont / Société Générale Group). It announces that an analyst firm (Gilbert Dupont) has initiated research coverage with a 'Buy' recommendation and a price target. This type of announcement, which informs the market about new analyst coverage, is typically classified as a general regulatory announcement or news release, often falling under the 'Regulatory Filings' (RNS) category if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). Since it is not a financial report itself, nor a management change, dividend notice, or proxy statement, RNS is the most appropriate general regulatory category for this market-facing news.
2024-04-05 French
MAAT URD 2024
Investor Presentation Classification · 95% confidence The document text explicitly identifies itself as a "DOCUMENT D’ENREGISTREMENT UNIVERSEL" (Universal Registration Document) filed with the AMF (Autorité des marchés financiers) on April 2, 2024. This type of comprehensive filing, which includes annual financial statements (IFRS and French GAAP for 2023), risk factors, management reports, and governance details, is the European equivalent of a comprehensive annual filing, most closely aligning with the scope of a US 10-K, but specifically named as a Universal Registration Document (URD) in this context. Given the provided definitions, the URD serves the function of a comprehensive annual report covering the full fiscal year (2023 financials mentioned). While '10-K' is the US equivalent, 'AR' (Audit Report/Information) is too narrow, and 'IR' (Interim Report) is incorrect as it covers the full year. Since the document is a complete, detailed annual filing, '10-K' is the most appropriate classification among the choices for a comprehensive annual report, even though the specific document type is URD.
2024-04-02 French
Inside Information / Other news releases
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new executive, Jonathan Chriqui, as Chief Business Officer. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The text focuses entirely on the new hire's background, responsibilities, and quotes from management regarding the appointment, confirming the classification.
2024-03-21 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new executive, Jonathan Chriqui, as Chief Business Officer. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice. Therefore, the appropriate classification is MANG.
2024-03-21 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.